Dataset opportunity
Bridgetolife — 医疗影像数据集机会
Bridgetolife 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
70.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗诊断人工智能市场在 2023 年的估值为 11 亿美元，预计复合年增长率为 25.2%（2024-2033 年）。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-12
Bridge to Life raises $110m to advance liver perfusion system’s rollout
medicaldevice-network.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗人工智能与诊断影像公司
Bridgetolife 提供来自临床试验的高价值医疗影像数据集，其中包括影像模态、专有机器灌注遥测技术（`iot_data`）以及相关的 `medical_records`。该多模态数据集的结构独特，适用于训练和验证诊断人工智能算法，因为它直接与 FDA 的 `regulatory` 提交相关联。
该数据位于全球医疗诊断人工智能市场中，该市场在 2023 年的估值为11 亿美元，预计将以25.2% 的复合年增长率增长。[4] 虽然访问需要应对其作为高度敏感的临床试验数据（HIPAA/GDPR）的地位以及与FDA 监管提交的联系等复杂性，但其稀有性和直接相关性使其成为旨在引领快速扩张的诊断人工智能领域的实体的关键资产。⚠ 尽职调查（有价值的数据，可协商访问）：高度敏感的临床试验数据（HIPAA/GDPR）；与 FDA 监管提交相关的数据；专有机器灌注遥测技术需要特定提取 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
该证据表明 Bridgetolife 持有来自一项关键的多中心临床试验的专有数据，该试验专注于低温含氧灌注（HOPE）用于器官移植。这个稀有的数据集结合了医疗影像、物联网设备输出和监管研究，非常适合寻求开发预测器官存活率模型的诊断人工智能公司。在 2023 年价值超过 11 亿美元的快速增长的人工智能诊断市场中，这些试验级数据为创建指导关键移植利用决策的工具提供了独特的基础。
See dimension details ↓- Dataset Specificity90
主导的 'medical_records'，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求异常高，这得益于医疗诊断人工智能市场 25.2% 的爆炸性复合年增长率，这导致了对高质量、监管级训练数据的激烈竞争。[4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — 该公司的核心业务是销售用于器官保存的医疗设备，而研发和试验产生的宝贵临床数据似乎是休眠的副产品，使其成为一个强有力的目标。问题：最初的来源描述“医疗影像数据集机会”不正确；该公司的业务是器官保存技术和解决方案，而不是
- Deep Qualification80
✓ 通过 — 目标是一家销售器官保存硬件的工具供应商；数据是其 FDA 强制性临床试验的副产品。数据所有权混合，涉及公司、医院和患者，并且高度敏感（HIPAA/GDPR），尽管价值很高，但访问起来很复杂。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该证据指向在关键临床试验期间生成的医疗影像集合，这对于诊断人工智能开发人员训练评估器官健康的模型非常有吸引力。
IoT / sensor data
该样本表明 VitaSmart™ 灌注系统的时间序列数据可用，这对于开发多模态人工智能至关重要，该人工智能可以根据实时器官指标预测移植成功率。
Regulatory records
该文本证据包括专注于识别用于移植利用的生物标志物的研究，提供了验证诊断人工智能临床效用所需的科学和监管背景。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Coverage
Scanned sources
Deliverable
Premium dataset report
Bridgetolife Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Diagnostics Market was valued at $1.1 Billion in 2023, with a projected CAGR of 25.2% (2024-2033) (source: Market.us). [4]. Investment score 70.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Streetdrone — 移动遥测数据集机会
View opportunity →移动出行Gatik — 移动遥测数据集机会
View opportunity →工业Renewableconnections — 工业传感器数据集机会
View opportunity →